Therapeutic area
Oncology
Solid tumors, hematologic malignancies, and immuno-oncology therapies targeting cancer cell survival and proliferation.
Core & active disease programs
Breast Cancer
$22.7B+ attributable cost
$2.4B$+ drug spend
104 assets · 3 indications
Multiple Myeloma
$13.7B+ attributable cost
$6.7B$+ drug spend
167 assets · 2 indications
Non-Small Cell Lung Cancer
$12.5B+ attributable cost
$4.8B$+ drug spend
610 assets · 7 indications
Acute Myeloid Leukemia
$4.3B+ attributable cost
129 assets · 2 indications
Provisional & emerging programs (50)Early clinical pipeline & single-asset indications
Solid Tumors
Ovarian Cancer
Colorectal Cancer
Non-Hodgkin Lymphoma
Renal Cell Carcinoma
Melanoma
Head and Neck Squamous Cell Carcinoma
Biliary Tract Cancer
Glioblastoma
Diffuse Large B-Cell Lymphoma
Hepatocellular Carcinoma
Myelodysplastic Syndromes
Myelofibrosis
Soft Tissue Sarcoma
Bladder Cancer
Cervical Cancer
Chronic Lymphocytic Leukemia
Follicular Lymphoma
Gastric Cancer
Hematologic Malignancies
Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma
Polycythemia Vera
Prostate Cancer
Bladder / Urothelial Cancer
Chronic Myeloid Leukemia
Cutaneous T-Cell Lymphoma
Merkel Cell Carcinoma
Metastatic Castration-Resistant Prostate Cancer
Small Cell Lung Cancer
Uveal Melanoma
Acute Lymphoblastic Leukemia
Anal Cancer
B-Cell Lymphoma
Bone Cancer
Brain Cancer
Brain Metastases
Central Nervous System Tumors
Endometrial Cancer
Esophageal Cancer
Essential Thrombocythemia
Gastrointestinal Stromal Tumor
Glioma
Mantle Cell Lymphoma
Nasopharyngeal Carcinoma
Neuroblastoma
Neuroendocrine Tumors
Oropharyngeal Cancer
Systemic Mastocytosis
Waldenstrom's Macroglobulinemia